Home / Business and Economy / Galderma Eyes ZO Skin Health in $1.5B Deal
Galderma Eyes ZO Skin Health in $1.5B Deal
14 Oct
Summary
- Galderma is acquiring ZO Skin Health for approximately $1.5 billion.
- The deal will expand Galderma's presence in the United States market.
- Dermatologist Zein Obagi founded ZO Skin Health in 2007.
Swiss skincare giant Galderma is poised to acquire the medical-grade skincare company ZO Skin Health in a transaction valued at approximately $1.5 billion. This potential deal, which could be announced soon, signifies a strategic move by Galderma to enhance its footprint in the United States market.
Galderma, a company with a diverse portfolio including brands like Cetaphil and Restylane, will expand its offerings with ZO's physician-distributed products. ZO Skin Health, established in 2007 by dermatologist Zein Obagi, specializes in effective skincare solutions sold through healthcare professionals.
ZO Skin Health's owner, investment firm Blackstone, had previously explored a sale with assistance from investment banks. The acquisition aligns with a market trend favoring clinically backed skincare brands with demonstrated efficacy and consistent demand.
